DANBURY, Conn., July 6 /PRNewswire-FirstCall/ — Biodel
Inc. (Nasdaq: BIOD) announced today that the following oral and
poster presentations describing results from studies of the
company’s product candidates will be presented during the 37th
Annual Meeting and Exposition of the Controlled Release Society in
Portland, Oregon, U.S.A. next
#51, Oral session on peptides and proteins, Monday July 12, 2010 4:00 PM (PT) “‘Smart’ Basal Insulin
Formulation that Releases Insulin in Response to Blood Glucose
Concentrations of Diabetic Swine,” to be presented by N. Kashyap,
#373, Poster session on peptides and proteins, Monday July 12, 2010 1:00 PM – 2:00 PM (PT) “Effect of EDTA
Concentration on Ultra-Rapid Action of VIAject® in Diabetic
Miniature Swine,” to be presented by Dr. R.
Pohl, Biodel Inc.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on
the development and commercialization of innovative treatments for
diabetes. Biodel’s product candidates are developed using
VIAdel(TM) technology, which reformulates existing FDA-approved
peptide drugs. Biodel’s new drug application for its most
advanced product candidate, VIAject(R), has been accepted for
review by the FDA with a Prescription Drug User Fee Act action date
of October 30, 2010.